TY - BOOK AU - Howlader, N. N. A. AU - Krapcho, M. AU - Miller, D. AU - Brest, A. AU - Yu, M. AU - Ruhl, J. AU - Tatalovich, Z. AU - Mariotto, A. AU - Lewis, D. R. AU - Chen, H. S. AU - Feuer, E. J. AU - Cronin, K. A. PY - 2019 DA - 2019// TI - SEER Cancer Statistics Review, 1975–2016, National Cancer Institute ID - Howlader2019 ER - TY - JOUR AU - Duffy, M. J. AU - Walsh, S. AU - McDermott, E. W. AU - Crown, J. PY - 2015 DA - 2015// TI - Biomarkers in breast Cancer: where are we and where are we going? JO - Adv Clin Chem VL - 71 UR - https://doi.org/10.1016/bs.acc.2015.05.001 DO - 10.1016/bs.acc.2015.05.001 ID - Duffy2015 ER - TY - JOUR AU - Mariotto, A. B. AU - Etzioni, R. AU - Hurlbert, M. AU - Penberthy, L. AU - Mayer, M. PY - 2017 DA - 2017// TI - Estimation of the number of women living with metastatic breast Cancer in the United States. Cancer epidemiology biomarkers & JO - Prevention VL - 26 ID - Mariotto2017 ER - TY - JOUR AU - Gobbini, E. AU - Ezzalfani, M. AU - Dieras, V. PY - 2018 DA - 2018// TI - Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort JO - Eur J Cancer VL - 96 UR - https://doi.org/10.1016/j.ejca.2018.03.015 DO - 10.1016/j.ejca.2018.03.015 ID - Gobbini2018 ER - TY - JOUR AU - Schmid, P. AU - Adams, S. AU - Rugo, H. S. PY - 2018 DA - 2018// TI - Atezolizumab and nab-paclitaxel in advanced triple-negative breast Cancer JO - N Engl J Med VL - 379 UR - https://doi.org/10.1056/NEJMoa1809615 DO - 10.1056/NEJMoa1809615 ID - Schmid2018 ER - TY - JOUR AU - Nanda, R. AU - Chow, L. Q. AU - Dees, E. C. PY - 2016 DA - 2016// TI - Pembrolizumab in patients with advanced triple-negative breast Cancer: phase Ib KEYNOTE-012 study JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2015.64.8931 DO - 10.1200/JCO.2015.64.8931 ID - Nanda2016 ER - TY - JOUR AU - Adams, S. AU - Schmid, P. AU - Rugo, H. S. PY - 2019 DA - 2019// TI - Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort a of the phase II KEYNOTE-086 study JO - Ann Oncol VL - 30 UR - https://doi.org/10.1093/annonc/mdy517 DO - 10.1093/annonc/mdy517 ID - Adams2019 ER - TY - JOUR AU - Hersom, M. AU - Jorgensen, J. T. PY - 2018 DA - 2018// TI - Companion and complementary diagnostics-focus on PD-L1 expression assays for PD-1/PD-L1 checkpoint inhibitors in non-small cell lung Cancer JO - Ther Drug Monit VL - 40 ID - Hersom2018 ER - TY - JOUR AU - Kim, J. M. AU - Chen, D. S. PY - 2016 DA - 2016// TI - Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure) JO - Ann Oncol VL - 27 UR - https://doi.org/10.1093/annonc/mdw217 DO - 10.1093/annonc/mdw217 ID - Kim2016 ER - TY - JOUR AU - Buttner, R. AU - Gosney, J. R. AU - Skov, B. G. PY - 2017 DA - 2017// TI - Programmed death-ligand 1 immunohistochemistry testing: a review of analytical assays and clinical implementation in non-small-cell lung Cancer JO - J Clin Oncol VL - 35 UR - https://doi.org/10.1200/JCO.2017.74.7642 DO - 10.1200/JCO.2017.74.7642 ID - Buttner2017 ER - TY - JOUR AU - Rimm, D. L. AU - Han, G. AU - Taube, J. M. PY - 2019 DA - 2019// TI - Reanalysis of the NCCN PD-L1 companion diagnostic assay study for lung cancer in the context of PD-L1 expression findings in triple-negative breast cancer JO - Breast Cancer Res VL - 21 UR - https://doi.org/10.1186/s13058-019-1156-6 DO - 10.1186/s13058-019-1156-6 ID - Rimm2019 ER - TY - JOUR AU - Rimm, D. L. AU - Han, G. AU - Taube, J. M. PY - 2017 DA - 2017// TI - A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non–small cell lung CancerAssessment of 4 assays for PD-L1 expression in NSCLCAssessment of 4 assays for PD-L1 expression in NSCLC JO - JAMA Oncol VL - 3 UR - https://doi.org/10.1001/jamaoncol.2017.0013 DO - 10.1001/jamaoncol.2017.0013 ID - Rimm2017 ER - TY - JOUR AU - Chalmers, Z. R. AU - Connelly, C. F. AU - Fabrizio, D. PY - 2017 DA - 2017// TI - Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden JO - Genome Med VL - 9 UR - https://doi.org/10.1186/s13073-017-0424-2 DO - 10.1186/s13073-017-0424-2 ID - Chalmers2017 ER - TY - JOUR AU - Schumacher, T. N. AU - Schreiber, R. D. PY - 2015 DA - 2015// TI - Neoantigens in cancer immunotherapy JO - Science VL - 348 UR - https://doi.org/10.1126/science.aaa4971 DO - 10.1126/science.aaa4971 ID - Schumacher2015 ER - TY - JOUR AU - Snyder, A. AU - Makarov, V. AU - Merghoub, T. PY - 2014 DA - 2014// TI - Genetic basis for clinical response to CTLA-4 blockade in melanoma JO - N Engl J Med VL - 371 UR - https://doi.org/10.1056/NEJMoa1406498 DO - 10.1056/NEJMoa1406498 ID - Snyder2014 ER - TY - JOUR AU - Rizvi, N. AU - Hellmann, M. AU - Snyder, A. PY - 2015 DA - 2015// TI - Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer JO - Science VL - 348 UR - https://doi.org/10.1126/science.aaa1348 DO - 10.1126/science.aaa1348 ID - Rizvi2015 ER - TY - JOUR AU - Hellmann, M. D. AU - Paz-Ares, L. PY - 2018 DA - 2018// TI - Lung Cancer with a high tumor mutational burden JO - N Engl J Med VL - 379 UR - https://doi.org/10.1056/NEJMc1808566 DO - 10.1056/NEJMc1808566 ID - Hellmann2018 ER - TY - JOUR AU - Offin, M. AU - Rizvi, H. AU - Tenet, M. PY - 2019 DA - 2019// TI - Tumor mutation burden and efficacy of EGFR-tyrosine kinase inhibitors in patients with EGFR-mutant lung cancers JO - Clin Cancer Res VL - 25 UR - https://doi.org/10.1158/1078-0432.CCR-18-1102 DO - 10.1158/1078-0432.CCR-18-1102 ID - Offin2019 ER - TY - JOUR AU - Rizvi, H. AU - Sanchez-Vega, F. AU - La, K. PY - 2018 DA - 2018// TI - Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung Cancer profiled with targeted next-generation sequencing JO - J Clin Oncol VL - 36 UR - https://doi.org/10.1200/JCO.2017.75.3384 DO - 10.1200/JCO.2017.75.3384 ID - Rizvi2018 ER - TY - JOUR AU - Hellmann, M. D. AU - Nathanson, T. AU - Rizvi, H. PY - 2018 DA - 2018// TI - Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer JO - Cancer Cell VL - 33 UR - https://doi.org/10.1016/j.ccell.2018.03.018 DO - 10.1016/j.ccell.2018.03.018 ID - Hellmann2018 ER - TY - JOUR AU - Hellmann, M. D. AU - Ciuleanu, T. E. AU - Pluzanski, A. PY - 2018 DA - 2018// TI - Nivolumab plus Ipilimumab in lung Cancer with a high tumor mutational burden JO - N Engl J Med VL - 378 UR - https://doi.org/10.1056/NEJMoa1801946 DO - 10.1056/NEJMoa1801946 ID - Hellmann2018 ER - TY - JOUR AU - Hellmann, M. D. AU - Callahan, M. K. AU - Awad, M. M. PY - 2018 DA - 2018// TI - Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer JO - Cancer Cell VL - 33 UR - https://doi.org/10.1016/j.ccell.2018.04.001 DO - 10.1016/j.ccell.2018.04.001 ID - Hellmann2018 ER - TY - JOUR AU - Yarchoan, M. AU - Hopkins, A. AU - Jaffee, E. M. PY - 2017 DA - 2017// TI - Tumor mutational burden and response rate to PD-1 inhibition JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMc1713444 DO - 10.1056/NEJMc1713444 ID - Yarchoan2017 ER - TY - JOUR AU - Johnson, D. B. AU - Frampton, G. M. AU - Rioth, M. J. PY - 2016 DA - 2016// TI - Targeted next generation sequencing identifies markers of response to PD-1 blockade JO - Cancer Immunol Res VL - 4 UR - https://doi.org/10.1158/2326-6066.CIR-16-0143 DO - 10.1158/2326-6066.CIR-16-0143 ID - Johnson2016 ER - TY - JOUR AU - Rosenberg, J. E. AU - Hoffman-Censits, J. AU - Powles, T. PY - 2016 DA - 2016// TI - Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial JO - Lancet VL - 387 UR - https://doi.org/10.1016/S0140-6736(16)00561-4 DO - 10.1016/S0140-6736(16)00561-4 ID - Rosenberg2016 ER - TY - JOUR AU - Dietlein, F. AU - Thelen, L. AU - Reinhardt, H. C. PY - 2014 DA - 2014// TI - Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches JO - Trends Genetics VL - 30 UR - https://doi.org/10.1016/j.tig.2014.06.003 DO - 10.1016/j.tig.2014.06.003 ID - Dietlein2014 ER - TY - JOUR AU - Rizvi, N. A. AU - Hellmann, M. D. AU - Snyder, A. PY - 2015 DA - 2015// TI - Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer JO - Science VL - 348 UR - https://doi.org/10.1126/science.aaa1348 DO - 10.1126/science.aaa1348 ID - Rizvi2015 ER - TY - JOUR AU - Nathanson, T. AU - Ahuja, A. AU - Rubinsteyn, A. PY - 2017 DA - 2017// TI - Somatic mutations and Neoepitope homology in melanomas treated with CTLA-4 blockade JO - Cancer Immunol Res VL - 5 UR - https://doi.org/10.1158/2326-6066.CIR-16-0019 DO - 10.1158/2326-6066.CIR-16-0019 ID - Nathanson2017 ER - TY - JOUR AU - Chen, Y. P. AU - Zhang, Y. AU - Lv, J. W. PY - 2017 DA - 2017// TI - Genomic analysis of tumor microenvironment immune types across 14 solid Cancer types: immunotherapeutic implications JO - Theranostics VL - 7 UR - https://doi.org/10.7150/thno.21471 DO - 10.7150/thno.21471 ID - Chen2017 ER - TY - JOUR AU - Chabanon, R. M. AU - Pedrero, M. AU - Lefebvre, C. AU - Marabelle, A. AU - Soria, J. C. AU - Postel-Vinay, S. PY - 2016 DA - 2016// TI - Mutational landscape and sensitivity to immune checkpoint blockers JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-16-0903 DO - 10.1158/1078-0432.CCR-16-0903 ID - Chabanon2016 ER - TY - JOUR AU - Buecher, B. AU - Cacheux, W. AU - Rouleau, E. AU - Dieumegard, B. AU - Mitry, E. AU - Lievre, A. PY - 2013 DA - 2013// TI - Role of microsatellite instability in the management of colorectal cancers JO - Digest Liver Dis VL - 45 UR - https://doi.org/10.1016/j.dld.2012.10.006 DO - 10.1016/j.dld.2012.10.006 ID - Buecher2013 ER - TY - JOUR AU - Le, D. T. AU - Uram, J. N. AU - Wang, H. PY - 2015 DA - 2015// TI - PD-1 blockade in tumors with mismatch-repair deficiency JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1500596 DO - 10.1056/NEJMoa1500596 ID - Le2015 ER - TY - JOUR AU - Hugo, W. AU - Zaretsky, J. M. AU - Sun, L. PY - 2016 DA - 2016// TI - Genomic and Transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma JO - Cell VL - 165 UR - https://doi.org/10.1016/j.cell.2016.02.065 DO - 10.1016/j.cell.2016.02.065 ID - Hugo2016 ER - TY - JOUR AU - Miao, D. AU - Margolis, C. A. AU - Gao, W. PY - 2018 DA - 2018// TI - Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma JO - Science VL - 359 UR - https://doi.org/10.1126/science.aan5951 DO - 10.1126/science.aan5951 ID - Miao2018 ER - TY - JOUR AU - Fuchs, C. S. AU - Doi, T. AU - Jang, R. W. PY - 2018 DA - 2018// TI - Safety and efficacy of Pembrolizumab Monotherapy in patients with previously treated advanced gastric and Gastroesophageal junction Cancer: phase 2 clinical KEYNOTE-059 trial JO - JAMA Oncol VL - 4 UR - https://doi.org/10.1001/jamaoncol.2018.0013 DO - 10.1001/jamaoncol.2018.0013 ID - Fuchs2018 ER - TY - JOUR AU - Campbell, B. B. AU - Light, N. AU - Fabrizio, D. PY - 2017 DA - 2017// TI - Comprehensive Analysis of Hypermutation in Human Cancer JO - Cell VL - 171 UR - https://doi.org/10.1016/j.cell.2017.09.048 DO - 10.1016/j.cell.2017.09.048 ID - Campbell2017 ER - TY - STD TI - Bonneville R, Krook MA, Kautto EA, et al. Landscape of microsatellite instability across 39 Cancer types. JCO Precision Oncol. 2017;2017:10.1200/PO.17.00073. https://doi.org/10.1200/PO.17.00073. ID - ref37 ER - TY - JOUR AU - Takamochi, K. AU - Takahashi, F. AU - Suehara, Y. PY - 2017 DA - 2017// TI - DNA mismatch repair deficiency in surgically resected lung adenocarcinoma: Microsatellite instability analysis using the Promega panel JO - Lung cancer (Amsterdam, Netherlands) VL - 110 UR - https://doi.org/10.1016/j.lungcan.2017.05.016 DO - 10.1016/j.lungcan.2017.05.016 ID - Takamochi2017 ER - TY - JOUR AU - Song, Z. AU - Cheng, G. AU - Xu, C. AU - Wang, W. AU - Shao, Y. AU - Zhang, Y. PY - 2018 DA - 2018// TI - Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer JO - Lung cancer (Amsterdam, Netherlands) VL - 118 UR - https://doi.org/10.1016/j.lungcan.2018.02.004 DO - 10.1016/j.lungcan.2018.02.004 ID - Song2018 ER - TY - JOUR AU - Zehir, A. AU - Benayed, R. AU - Shah, R. H. PY - 2017 DA - 2017// TI - Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients JO - Nat Med VL - 23 UR - https://doi.org/10.1038/nm.4333 DO - 10.1038/nm.4333 ID - Zehir2017 ER - TY - JOUR AU - Hou, Y. AU - Nitta, H. AU - Parwani, A. V. AU - Li, Z. PY - 2019 DA - 2019// TI - PD-L1 and CD8 are associated with deficient mismatch repair status in triple-negative and HER2-positive breast cancers JO - Hum Pathol VL - 86 UR - https://doi.org/10.1016/j.humpath.2018.12.007 DO - 10.1016/j.humpath.2018.12.007 ID - Hou2019 ER - TY - JOUR AU - Mills, A. M. AU - Dill, E. A. AU - Moskaluk, C. A. AU - Dziegielewski, J. AU - Bullock, T. N. AU - Dillon, P. M. PY - 2018 DA - 2018// TI - The relationship between mismatch repair deficiency and PD-L1 expression in breast carcinoma JO - Am J Surg Pathol VL - 42 UR - https://doi.org/10.1097/PAS.0000000000000949 DO - 10.1097/PAS.0000000000000949 ID - Mills2018 ER - TY - JOUR AU - Wen, Y. H. AU - Brogi, E. AU - Zeng, Z. PY - 2012 DA - 2012// TI - DNA mismatch repair deficiency in breast carcinoma: a pilot study of triple-negative and non-triple-negative tumors JO - Am J Surg Pathol VL - 36 UR - https://doi.org/10.1097/PAS.0b013e3182627787 DO - 10.1097/PAS.0b013e3182627787 ID - Wen2012 ER - TY - JOUR AU - Vranic, S. AU - Palazzo, J. AU - Sanati, S. PY - 2019 DA - 2019// TI - Potential novel therapy targets in neuroendocrine carcinomas of the breast JO - Clin Breast Cancer VL - 19 UR - https://doi.org/10.1016/j.clbc.2018.09.001 DO - 10.1016/j.clbc.2018.09.001 ID - Vranic2019 ER - TY - JOUR AU - Balbas, M. D. AU - Burgess, M. R. AU - Murali, R. PY - 2014 DA - 2014// TI - MAGI-2 scaffold protein is critical for kidney barrier function JO - Proc Natl Acad Sci U S A VL - 111 UR - https://doi.org/10.1073/pnas.1417297111 DO - 10.1073/pnas.1417297111 ID - Balbas2014 ER - TY - JOUR AU - Tolkacheva, T. AU - Boddapati, M. AU - Sanfiz, A. AU - Tsuchida, K. AU - Kimmelman, A. C. AU - Chan, A. M. PY - 2001 DA - 2001// TI - Regulation of PTEN binding to MAGI-2 by two putative phosphorylation sites at threonine 382 and 383 JO - Cancer Res VL - 61 ID - Tolkacheva2001 ER - TY - JOUR AU - Vazquez, F. AU - Grossman, S. R. AU - Takahashi, Y. AU - Rokas, M. V. AU - Nakamura, N. AU - Sellers, W. R. PY - 2001 DA - 2001// TI - Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex JO - J Biol Chem VL - 276 UR - https://doi.org/10.1074/jbc.C100556200 DO - 10.1074/jbc.C100556200 ID - Vazquez2001 ER - TY - JOUR AU - Wu, X. AU - Hepner, K. AU - Castelino-Prabhu, S. PY - 2000 DA - 2000// TI - Evidence for regulation of the PTEN tumor suppressor by a membrane-localized multi-PDZ domain containing scaffold protein MAGI-2 JO - Proc Natl Acad Sci U S A VL - 97 UR - https://doi.org/10.1073/pnas.97.8.4233 DO - 10.1073/pnas.97.8.4233 ID - Wu2000 ER - TY - JOUR AU - David, S. N. AU - Arnold Egloff, S. A. AU - Goyal, R. PY - 2018 DA - 2018// TI - MAGI2 is an independent predictor of biochemical recurrence in prostate cancer JO - Prostate VL - 78 UR - https://doi.org/10.1002/pros.23506 DO - 10.1002/pros.23506 ID - David2018 ER - TY - JOUR AU - Goldstein, J. AU - Borowsky, A. D. AU - Goyal, R. PY - 2016 DA - 2016// TI - MAGI-2 in prostate cancer: an immunohistochemical study JO - Hum Pathol VL - 52 UR - https://doi.org/10.1016/j.humpath.2016.01.003 DO - 10.1016/j.humpath.2016.01.003 ID - Goldstein2016 ER - TY - JOUR AU - Goldstein, J. AU - Goyal, R. AU - Roland, J. T. PY - 2016 DA - 2016// TI - MAGI-2 is a sensitive and specific marker of prostatic adenocarcinoma: a comparison with AMACR JO - Am J Clin Pathol VL - 146 UR - https://doi.org/10.1093/ajcp/aqw111 DO - 10.1093/ajcp/aqw111 ID - Goldstein2016 ER - TY - JOUR AU - Hu, Y. AU - Li, Z. AU - Guo, L. PY - 2007 DA - 2007// TI - MAGI-2 inhibits cell migration and proliferation via PTEN in human hepatocarcinoma cells JO - Arch Biochem Biophys VL - 467 UR - https://doi.org/10.1016/j.abb.2007.07.027 DO - 10.1016/j.abb.2007.07.027 ID - Hu2007 ER - TY - JOUR AU - Mahdian, R. AU - Nodouzi, V. AU - Asgari, M. PY - 2014 DA - 2014// TI - Expression profile of MAGI2 gene as a novel biomarker in combination with major deregulated genes in prostate cancer JO - Mol Biol Rep VL - 41 UR - https://doi.org/10.1007/s11033-014-3491-0 DO - 10.1007/s11033-014-3491-0 ID - Mahdian2014 ER - TY - JOUR AU - Zhao, J. AU - Chen, A. X. AU - Gartrell, R. D. PY - 2019 DA - 2019// TI - Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma JO - Nat Med VL - 25 UR - https://doi.org/10.1038/s41591-019-0349-y DO - 10.1038/s41591-019-0349-y ID - Zhao2019 ER - TY - JOUR AU - Cretella, D. AU - Digiacomo, G. AU - Giovannetti, E. AU - Cavazzoni, A. PY - 2019 DA - 2019// TI - PTEN alterations as a potential mechanism for tumor cell escape from PD-1/PD-L1 inhibition JO - Cancers VL - 11 UR - https://doi.org/10.3390/cancers11091318 DO - 10.3390/cancers11091318 ID - Cretella2019 ER -